# Rheumatology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Flannery O'Connor (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML046-SYN-TD
- Date: 1950-04-22
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rafael Okonjo-Strand, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Augusta Pemberton-Diallo, MD

## Reason for consultation

Inflammatory polyarthritis with fevers, fatigue, a malar-pattern rash, leukopenia, lymphopenia, mild anemia and thrombocytopenia, and protein and blood in the urine in a woman of 25. I suspect systemic lupus erythematosus with kidney involvement rather than rheumatoid arthritis. Please confirm the diagnosis, assess the kidneys, and plan treatment with her. **S**

## History

Ms. O'Connor is seen at the request of Dr. Pemberton-Diallo. For three months she has had symmetrical pain and swelling of the hand joints, wrists, and knees with an hour of morning stiffness, evening fevers, fatigue, a facial rash after sun, some hair shedding, and a painless sore on the roof of her mouth. She has no chest pain on breathing, breathlessness, leg swelling, seizures, or headaches. She had an operation for a floating kidney some years ago. Her father had lupus. She takes only acetaminophen. She asked to hear everything directly and plainly. **S**

## Examination

| System | Finding |
|---|---|
| Skin | Red, slightly raised rash over both cheeks and the bridge of the nose, sparing the nasolabial folds; diffuse thinning of the scalp hair |
| Mouth | Painless 4 mm ulcer on the hard palate |
| Musculoskeletal | Synovitis of the second and third knuckles and middle finger joints of both hands and both wrists; small knee effusions; no deformity |
| Cardiovascular and respiratory | No rub; chest clear; no edema |

BP 136/84 mmHg; pulse 92 bpm; respirations 16/min; temperature 37.6 °C; oxygen saturation 98% on room air; weight 59.6 kg; BMI 21.1 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Pemberton-Diallo's referral and the blood and urine tests from nine days ago; the ANA, anti-dsDNA, anti-Sm, complements, antiphospholipid antibodies, lupus anticoagulant, repeat urine protein-to-creatinine ratio, and urine microscopy drawn here this morning, which returned this afternoon; hepatitis B, hepatitis C, HIV, and pregnancy tests. ANA titer (HEp-2 immunofluorescence): 640 (high); Anti-dsDNA: 186 [IU]/mL (high); Anti-Sm: 42 U/mL (high); Complement C3: 62 mg/dL (low); Complement C4: 8 mg/dL (low); Anticardiolipin IgG: 6 U/mL; Anticardiolipin IgM: 4 U/mL; Anti-beta-2 glycoprotein I IgG: 3 U/mL; Anti-beta-2 glycoprotein I IgM: 2 U/mL; Lupus anticoagulant (dRVVT screen-to-confirm ratio): 1.04; Urine protein-to-creatinine ratio: 1.8 g/g (high); Urine red cells: 22 /[HPF] (high); Creatinine: 0.8 mg/dL; eGFR: 101 mL/min/1.73 m². All results are synthetic.

## Assessment

1. **Systemic lupus erythematosus** (M32.19). ANA 1:640 meets the EULAR/ACR entry criterion, and the weighted criteria score 32 (fever, thrombocytopenia, acute cutaneous lupus, joint involvement, proteinuria, low C3 and C4, anti-dsDNA and anti-Sm), so she is classified as having lupus; anti-dsDNA 186 and anti-Sm 42 are highly specific. Disease activity is high (SLEDAI-2K 23). The arthritis of lupus mimics rheumatoid arthritis, which is why it is often misnamed. Antiphospholipid antibodies and lupus anticoagulant are negative. **S**
2. **Kidney involvement** (R80.9). A protein-to-creatinine ratio of 1.8 g/g with dysmorphic red cells and a red cell cast and normal creatinine almost certainly means lupus nephritis. A kidney biopsy is needed now, because the class decides treatment. **S**
3. **Treatment**. Hydroxychloroquine for every patient with lupus, at 5 mg/kg or less, now. If the biopsy shows class III or IV nephritis: three days of pulse methylprednisolone, then prednisone from about 0.5 mg/kg tapered to 5 mg a day or less by six months, with mycophenolate 2 to 3 g a day plus a second agent, either belimumab or a calcineurin inhibitor such as voclosporin, continued for years after a complete response. An angiotensin receptor blocker for proteinuria and blood pressure. If the class were V alone, the plan would change. **S**
4. **Vaccination and infection**. Non-live vaccines are best given before immunosuppression: PCV20 and recombinant zoster can be given today and influenza was given in October. She is immune to hepatitis B by vaccination and negative for hepatitis C and HIV. Pneumocystis prophylaxis can be considered while the prednisone dose is high; sulfonamides are best avoided in lupus. **S**
5. **Contraception and pregnancy**. Mycophenolate causes birth defects and needs highly effective contraception. With negative antiphospholipid tests, estrogen is not contraindicated by clotting risk, but an intrauterine system is the most effective choice during active disease. Pregnancy should wait for at least six months of quiet disease on compatible medicines. **S**
6. **Bone, avascular necrosis, and eyes**. High-dose glucocorticoids threaten bone and can cause avascular necrosis of the hip, especially at high doses. A DXA at the start, vitamin D and calcium, and the lowest glucocorticoid dose protect her; new hip, groin, or knee pain needs prompt MRI. Hydroxychloroquine needs a baseline eye examination with OCT and visual fields within the first year. **S**
7. **Family history**. Lupus clusters in families, and first-degree relatives have a much higher relative risk, although the absolute risk to any one relative is low. No genetic test is needed. She was told that treatment and outcomes today are very different from those of earlier generations. **S**

## Recommendations

1. Hydroxychloroquine 300 mg daily now, long term; baseline eye examination within the first year, then yearly from five years.
2. Ultrasound-guided kidney biopsy within days.
3. For class III or IV nephritis: methylprednisolone 500 mg daily for three days, then prednisone 30 mg tapered to 5 mg or less by six months; mycophenolate mofetil, 500 mg twice daily for a week, then 1000 mg twice daily; and belimumab or voclosporin, chosen with her.
4. Losartan 25 mg daily, with potassium and creatinine in two to four weeks; blood pressure below 130/80.
5. PCV20 and recombinant zoster dose 1 today, zoster dose 2 in one to two months, seasonal influenza and COVID-19; no live vaccines.
6. Levonorgestrel intrauterine system before mycophenolate, with a negative pregnancy test.
7. DXA at the start of glucocorticoids, vitamin D3 and dietary calcium; report hip, groin, or knee pain.
8. Daily sun protection; no NSAIDs; blood counts weekly for the first month on mycophenolate, then less often; urine protein, sediment, creatinine, and serology every three months.
9. Every result to be explained to her directly, with a written copy, and shared only with the people she names.

## Strengths and supports

- Strengths: a sharp, ironic sense of humor and a steady religious faith; supports: friends and a writing community; she prefers to keep her health out of conversations about her work **S**

## Communication

Discussed with Dr. Pemberton-Diallo the same day. Ms. O'Connor was told the diagnosis directly, has a written summary, and agreed to the biopsy and the plan; she will hear the biopsy result from this clinic by telephone first. **S**

## Follow-up

Kidney biopsy in two days; this clinic will give her the result and start treatment at the primary care visit in one week, then see her every three months with weekly blood counts in the first month. **S**

## Guideline basis

- 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 2019;71(9):1400-1412 (2019), EULAR and American College of Rheumatology
- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023), EULAR
- 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol 2025;77(9):1115-1135 (2024), American College of Rheumatology
- Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology 2016;123(6):1386-1394 (2016), American Academy of Ophthalmology
- 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol 2023;75(3):333-348 (2022), American College of Rheumatology
- 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (2022), American College of Rheumatology
- 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care Res 2020;72(4):461-488 (2020), American College of Rheumatology
